bioXcelerate AI, a division of Optima Partners at ASHG 2026

Oct 20–24, 2026 Montréal, Canada ~7.5k attendees Website

bioXcelerate AI, a division of Optima Partners at ASHG 2026 in Montréal: 2 presentations (2 posters).

Organization	ASHG 2026 Attendance
bioXcelerate AI, a division of Optima Partners Edinburgh, UK	2 Scientists
bioxcelerateai.com\|LinkedIn Subsidiary BioXcelerate AI sells genomics-led drug-discovery analytics, multi-omics methods, and health-data science services. Its customers include pharmaceutical companies, biotech firms, and public health organizations. bioXcelerate AI applied its DiscoveryX and GraphX platforms to Parkinson's disease research, integrating genetic and multi-omics datasets. › bioXcelerate AI applied its DiscoveryX and GraphX platforms to Parkinson's disease research, integrating genetic and multi-omics datasets. 2026-04 · source bioXcelerate AI outlined agile operating models to help pharma R&D leaders speed up drug-discovery decision-making. 2025-11 · source bioXcelerate AI presented DiscoveryX Parkinson's disease research at ASHG 2025, showcasing its integrative multi-omics analysis platform. 2025-10 · source Source: company newsroom Financials not disclosed › Received investment from Growth Capital Partners supporting expansion; amount and date are not public. “This recognition follows a period of sustained growth, supported by investment from Growth Capital Partners, enabling continued expansion of its capabilities, team and client base.” Source: funding announcement Currently hiring: 9 open roles › Source: careers page	Poster Wed Oct 21 2:30 pm Part of Statistical Genetics and Genetic Epidemiology Poster Wednesday Session An integrative framework leveraging trans-pQTLs for therapeutic target discovery Exhibit & Poster Hall · Board 8365W Molecular therapeuticsExpression quantitative trait lociGenome-wide association study Poster Thu Oct 22 4:15 pm Part of Epigenomics Poster Thursday Session Causal inference and multi-omic integration reveal therapeutic target opportunities in Parkinson’s disease Exhibit & Poster Hall · Board 7044T EpigeneticsMachine learningMulti-omicsNeurodegeneration

Organization

ASHG 2026 Attendance

bioXcelerate AI, a division of Optima Partners

Edinburgh, UK

2 Scientists

bioxcelerateai.com|LinkedIn

Subsidiary

BioXcelerate AI sells genomics-led drug-discovery analytics, multi-omics methods, and health-data science services. Its customers include pharmaceutical companies, biotech firms, and public health organizations.

bioXcelerate AI applied its DiscoveryX and GraphX platforms to Parkinson's disease research, integrating genetic and multi-omics datasets.

›

bioXcelerate AI applied its DiscoveryX and GraphX platforms to Parkinson's disease research, integrating genetic and multi-omics datasets.

2026-04 · source

bioXcelerate AI outlined agile operating models to help pharma R&D leaders speed up drug-discovery decision-making.

2025-11 · source

bioXcelerate AI presented DiscoveryX Parkinson's disease research at ASHG 2025, showcasing its integrative multi-omics analysis platform.

2025-10 · source

Source: company newsroom

Financials not disclosed

›

Received investment from Growth Capital Partners supporting expansion; amount and date are not public.

“This recognition follows a period of sustained growth, supported by investment from Growth Capital Partners, enabling continued expansion of its capabilities, team and client base.”

Source: funding announcement

Currently hiring: 9 open roles

›

Source: careers page

Poster

Wed Oct 21
2:30 pm

Part of Statistical Genetics and Genetic Epidemiology Poster Wednesday Session

An integrative framework leveraging trans-pQTLs for therapeutic target discovery

Exhibit & Poster Hall · Board 8365W

Molecular therapeuticsExpression quantitative trait lociGenome-wide association study

Poster

Thu Oct 22
4:15 pm